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Abstract P2Y12 receptor is a Gi-coupled adenosine diphos-
phate (ADP) receptor with a critical role in platelet aggrega-
tion. It contains two potential N-linked glycosylation sites at its
extra cellular amino-terminus, which may modulate its activity.
Studies of both tunicamycin treatment and site-directed muta-
genesis have revealed a dispensable role of the N-linked glyco-
sylation in the receptor’s surface expression and ligand binding
activity. However, the non-glycosylated P2Y12 receptor is defec-
tive in the P2Y12-mediated inhibition of the adenylyl cyclase
activity. Thus the study uncovers an unexpected vital role of
N-linked glycans in receptor’s signal transducing step but not
in surface expression or ligand binding.
* 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Extracellular nucleotides act as potent signaling molecules
that trigger a broad range of physiological responses including
cardiac muscle contraction, chloride secretion, pain initiation,
and platelet aggregation [1^3]. These nucleotides can be re-
leased from various cell types including nerve cells, platelets,
chroma⁄n cells, and endothelial cells. They then activate two
types of P2 purinergic receptors at the cell surface: P2X and
P2Y receptors [1^4]. The P2X receptors are non-selective cat-
ion channels gated by adenosine triphosphate (ATP) [5] while
P2Y receptors are G protein-coupled receptors. Eight mam-
malian P2Y receptors have been identi¢ed thus far including
P2Y12, P2Y4, P2Y6, P2Y1114 [6]. Pharmacologically, P2Y
receptors can be subdivided into the adenine nucleotide-pre-
ferring receptors mainly responding to adenosine diphosphate
(ADP) and ATP (P2Y1, P2Y1113), the uracil nucleotide-pre-
ferring receptors responding to uridine triphosphate (UTP) or
uridine diphosphate (UDP) (P2Y4 and P2Y6), receptors of
mixed selectivity (P2Y2), and recent UDP-glucose receptor
(P2Y14) [6]. P2Y receptors can also be subdivided into ¢ve
Gq-coupled subtypes (P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11)
and three Gi-coupled subtypes (P2Y12, P2Y13, P2Y14) [7]. Ad-
ditionally, the P2Y11 receptor can couple to Gs and activate
adenylyl cyclase [8].
The P2Y12 receptor [9,10], expressed mainly in brain and
platelets, is one of the four purinergic receptors that can be
activated selectively by ADP. Together with the Gq-coupled
P2Y1 receptor [11,12], the Gi-coupled P2Y12 receptor responds
to ADP with inhibition of stimulated adenylyl cyclase and
plays an essential role in the ADP-induced platelet aggrega-
tion [11^15]. An autosomal deletion in the coding region of
the P2Y12 gene was found in a family with a bleeding disorder
and impaired platelet aggregation [10], con¢rming its function
in vivo. The P2Y12 receptor has also been shown to be the
target of clopidogrel, a potent anti-thrombotic drug that in-
hibits platelet aggregation [13,16].
N-linked glycosylation has been shown to be essential for
the surface expression and ligand potency of P2X receptors
such as P2X1 [17], P2X2 [18,19] and P2X4 receptor [20]. How-
ever, roles of the N-linked glycans of P2Y receptors remain
unknown. In this study, we have investigated the involvement
of N-linked glycosylation in the surface expression, ligand
binding and signaling function of the P2Y12 receptor. Both
tunicamycin treatment and site-directed mutagenesis ap-
proaches have demonstrated that N-linked glycosylation is
not essential for the surface tra⁄cking and ligand binding
of the receptor. Nonetheless, we have found that the N-glycan
modi¢cation of the receptor is important for the signal trans-
duction function upon ligand binding.
2. Materials and methods
2.1. DNA constructs and site-directed mutagenesis
The N-terminal hemagglutinin (HA) tag (YPYDVPDYAL) and
C-terminal 1D4 tag (NLETSQVAPA) were incorporated in polymer-
ase chain reaction (PCR) primer sequences just before initiator me-
thionine and termination codon of P2Y12 receptor respectively. The
site-directed mutagenesis of replacing Asn6 and/or Asn13 by Gln was
carried out with the QuickChange site-directed mutagenesis kit (Stra-
tagene, La Jolla, CA, USA). All PCR products were gel puri¢ed and
subcloned into pSEMD2 vector behind murine CMV promoter. All
constructs were veri¢ed by double strand sequencing.
2.2. Cell culture, transfection, tunicamycin treatment, and membrane
preparation
All mammalian cell lines (CHO-DHFR minus and cos) were grown
as described earlier [21]. Transfections were carried out using the lipo-
fectamine method (Invitrogen, Carlsbad, CA, USA). Tunicamycin
was prepared in sterile Me2SO and added to a ¢nal concentration
of 5 Wg/ml, while the control cells received Me2SO alone. Cells were
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analyzed after a 48-h incubation at 37‡C. For membrane prepara-
tions, cells were resuspended in lysis bu¡er (50 mM Tris^HCl, pH
7.5, 4 mM ethylenediamine tetraacetic acid (EDTA), pH 7.5, complete
protease inhibitors), and homogenized in ice by Duall tissue grinder
(Kontes, Vineland, NJ, USA). After spinning homogenates at 700Ug,
membranes were pelleted at 100 000Ug (Beckman, Ultracentrifuge,
rotor 70.1) for 30 min at 4‡C. Membrane pellets were resuspended
in membrane bu¡er (50 mM Tris^HCl, pH 7.5, 0.15 M NaCl, 4 mM
EDTA, 20% glycerol, complete protease inhibitors).
2.3. Radioligand binding
P2Y12-expressing CHO cells were incubated with di¡erent concen-
trations of [3H]2-methyl-thiol-adenosine diphosphate (2MeSADP)
(Moravek Biochemicals Inc, Brea, CA, USA) for 5 min at 25‡C. After
incubation, the reactions were stopped by rapid ¢ltration through
Whatman GF/B glass ¢ber ¢lters. The ¢lters were then rinsed with
Tris-bu¡ered saline (TBS), dried in air and counted with a liquid
scintillation counter. The 2MeSADP speci¢c binding was calculated
by subtracting the non-speci¢c binding de¢ned with 150 WM unlabeled
2MeSADP. For membrane binding experiments, the reactions were
incubated for 2 min at 25‡C, and HAWP nitrocellulose ¢lters (Milli-
pore, Bedford, MA, USA) were used for rapid ¢ltration. For the
competition studies, 10 nM [3H]2MeSADP was added to aliquots of
cells that were incubated with several concentrations of 2MeSADP or
2-methyl-thiol-adenosine monophosphate (2MeSAMP) (Alexis Corp.,
San Diego, CA, USA).
2.4. Flow cytometry analysis and Western analysis
Approximately, 106 cells lifted with ethyleneglycol-bis-(L-amino-
ethylether)-N,N,NP,NP-tetraacetic acid (EGTA) and washed with
phosphate-bu¡ered saline (PBS), were incubated with rat monoclonal
anti-HA 3F10 antibody or puri¢ed rat IgG1U (10 Wg/ml each) for 1 h
at 4‡C. After a second wash, cells were labeled with anti-rat IgG1/
IgG2a-£uorescein isothiocyanate (FITC) (1:100 dilution) for 1 h at
4‡C. Cells were then washed twice and analyzed with a £uores-
cence-activated cell sorter (FACS)-Calibur £ow cytometer (Becton
Dickinson, Mountain view, CA, USA). For Western analysis, samples
were run on 4^20% sodium dodecyl sulfate^polyacrylamide gel elec-
trophoresis (SDS^PAGE) gel (Invitrogen, Carlsbad, CA, USA) at 120
V and then transferred to nitrocellulose membrane. Anti-HA 3F10
antibody peroxidase conjugate was used in a 1:500 dilution. Goat
anti-mouse IgG peroxidase conjugate was used in a 1:2000 dilution.
The chemiluminescent signals (Supersignal kit, Pierce, Rockford, IL,
USA) were detected through FluorChem Imaging (Alpha Innotech
Corp, San Leandro, CA, USA).
2.5. Cellular cyclic AMP (cAMP) measurement
Wild-type or mutant HA-P2Y12-expressing cells were resuspended
in Dulbecco’s modi¢ed Eagle’s medium (DMEM) with 1 mM 3-iso-
butyl-1-methylxanthine (IBMX). The cells were exposed to various
concentrations of 2MeSADP with 1 WM forskolin dissolved in
DMEM containing 1 mM IBMX for 15 min at 37‡C. The cells
were harvested by centrifugation and lysed with 0.1 M HCl with boil-
ing. Intracellular cAMP was measured using a direct cAMP enzyme
immunoassay kit (Assay Designs, Ann Arbor, MI, USA) following
the manufacturer’s instructions. The cAMP concentrations were cal-
culated by the displacement curve obtained from the standard
cAMPs.
3. Results
3.1. Stable expression of P2Y12 receptor in CHO cells
In order to study structure and function of the P2Y12 re-
ceptor, stably expressing P2Y12 receptor with an amino-termi-
nal HA tag and a carboxy-terminal 1D4 tag was achieved by
transfecting CHO-DHFR3 cells with the receptor-expressing
plasmid and by selecting clones resistant to 100 nM metho-
trexate. The stable clones were screened by immunoblot de-
tection with rat monoclonal anti-HA 3F10 antibody. Out of
80 clones screened, one of the high expressing clones (100-17)
was chosen for further studies. As shown in Fig. 1A, the anti-
HA antibody 3F10 recognized a predominant band with an
approximate molecular weight of 64 kDa (estimated 41.7
kDa), which is consistent with the notion that P2Y12 is a
glycoprotein. To con¢rm whether the HA tagged P2Y12 re-
ceptor can bind ADP, the stable cell line was also measured
for the whole cell binding to [3H]2MeSADP (Fig. 1B). The
clone displays a Kd of approximately 5 nM and a Bmax of 2^3
pmol/106 cells. To determine the binding speci¢city of the HA
tagged receptor, competition binding experiments were carried
out in the stable cell line (Fig. 1C). The IC50 value of 2Me-
SADP is around 25 nM, whereas IC50 of 2MeSAMP is
around 16 WM. These values are consistent with the previously
reported values [16]. Surface expression of the wild-type P2Y12
in the stable cell line was con¢rmed by £ow cytometry anal-
Fig. 1. Stable expression of the P2Y12 receptor in CHO cells. A:
Immunodetection of the P2Y12 receptor with anti-HA antibody. The
whole cell extracts of the control CHO cells (lane 1) and the P2Y12-
expressing CHO cells (100-17) (lane 2) were separated by 4^20%
SDS^PAGE and immunoblotted with rat monoclonal anti-HA 3F10
antibody. B: Saturation binding of [3H]2MeSADP to the P2Y12-
expressing cells. The radioligand binding assay was performed as
described in Section 2. Cells were incubated with 1^50 nM
[3H]2MeSADP in the absence or presence of 150 WM unlabeled
2MeSADP. C: Competition for [3H]2MeSADP binding to the
P2Y12-expressing cells. 10 nM [3H]2MeSADP was added with cell
aliquots in the presence of 2MeSADP or 2MeSAMP. The data are
the meansUS.D. (n=4).
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ysis using rat monoclonal antibody directed against the HA
tag at the amino-terminus of the receptor (see Fig. 2A).
3.2. Treatment with tunicamycin has no e¡ect on the surface
expression and ligand binding of the P2Y12 receptor
Analysis of its amino acid sequence [9,10] predicts that the
human P2Y12 receptor contains two consensus sequences for
N-linked glycosylation at residues 6 and 13 within its extra-
cellular amino-terminus. To study the role of N-linked glyco-
sylation on cell surface expression, we used tunicamycin, an
inhibitor that speci¢cally inhibits the ¢rst step in the forma-
tion of the core oligosaccharide in N-linked glycosylation. The
P2Y12 stable cell line 100-17 was treated with 5 Wg/ml of tu-
nicamycin or with Me2SO solvent for 48 h. Cells were then
labeled with anti-HA antibody for the £ow cytometry analy-
sis. As shown in Fig. 2A, the P2Y12 receptors in tunicamycin-
treated and mock-treated cells were both detected at the cell
surfaces. When cell extracts from these samples were analyzed
on SDS^PAGE and immunoblotted with anti-HA antibody,
the apparent molecular weight of P2Y12 decreased to approx-
imately 42 kDa in the tunicamycin-treated cells (Fig. 2B, lane
2), a size consistent with the estimated molecular weight of
P2Y12 with tags (41.7 kDa). Moreover, the size of the protein
expressed in tunicamycin-treated cells was identical to that of
a mutant P2Y12 receptor lacking two glycosylation sites (see
below), indicating that the tunicamycin treatment successfully
prevented the N-linked glycosylation of the receptor. These
results suggest that N-linked glycosylation is not required
for surface expression of the P2Y12 receptor.
To assess the speci¢c binding of [3H]2MeSADP to the non-
glycosylated P2Y12 receptors in the tunicamycin-treated cells,
saturation whole cell binding studies were performed (Fig.
2C). Analysis of the [3H]2MeSADP binding data revealed
that the mock-treated cells had a Kd value of 4.6 nM and a
Bmax value of 3.6 pmol/106 cells, whereas the tunicamycin-
treated cells had a Kd value of 9.6 nM and a Bmax value of
3.89 pmol/106 cells. These results indicate that the ligand
binding properties of non-glycosylated P2Y12 receptors in tu-
nicamycin-treated cells are similar to that of the wild-type
receptors. Since [3H]2MeSADP is membrane impermeable,
this result also supports the £ow cytometry analysis data
showing that the non-glycosylated P2Y12 receptor is present
on the cell surface.
3.3. Site-directed mutagenesis further con¢rms that the glycans
carried at Asn6 and Asn13 of the P2Y12 receptor are not
required for its surface expression and ligand binding
activity
To further con¢rm the roles of N-linked glycosylation,
Asn6 and Asn13 of the glycosylation sites were mutated to
Gln by site-directed mutagenesis either individually or simul-
taneously to prevent glycosylation. The resulting mutant
P2Y12 receptors were transiently expressed in COS-7 cells
and the protein expression was examined by immunoblotting
Fig. 2. Treatments with tunicamycin have no e¡ect on the surface expression and ligand binding of the P2Y12 receptor. A: The P2Y12-express-
ing cells, treated with tunicamycin or with Me2SO alone, were stained with anti-HA monoclonal antibody 3F10 or isotypic rat IgG1, and sub-
jected to FACS analysis, as described in Section 2. B: The P2Y12-expressing cells were incubated for 48 h in the presence of Me2SO (lane 1) or
tunicamycin (lane 2). The whole cell extracts were resolved in 4^20% SDS^PAGE and immunoblotted with rat anti-HA 3F10 antibody. C: The
[3H]2MeSADP binding of the tunicamycin-treated or the mock-treated cells was measured as described in Section 2. The data are the
meansUS.D. (n=2).
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with anti-HA. As shown in Fig. 3A, substituting either Asn6
(lane 3) or Asn13 (lane 2) with Gln caused a faster migration
of P2Y12 in SDS^PAGE, suggesting the mutant receptors re-
ceive fewer N-glycan modi¢cations than the wild-type recep-
tor. When both Asn6 and Asn13 were mutated to Gln (lane 1),
one single 42-kDa band of P2Y12 was detected by the anti-HA
antibody, which is identical to the migration of the deglyco-
sylated band shown in Fig. 2C. These results indicate that
both Asn6 and Asn13 were utilized for N-linked glycosylation
in vivo. To determine the cell surface expression of the mutant
receptors, COS-7 cells transiently transfected with the mutant
constructs were labeled with anti-HA antibody and subjected
to FACS analysis. As shown in Fig. 3B, all three mutant
receptors (N6Q, N13Q, N6Q/N13Q) exhibit almost identical
surface expression patterns to the wild-type receptor in the
£ow cytometry analysis data, which is consistent with the
results of tunicamycin treatments (Fig. 2A). All these data
indicate that N-linked glycosylation is not essential for the
surface expression of the P2Y12 receptor.
To characterize the ligand binding of the N-linked mutants
Fig. 3. N-linked glycans at Asn6 and Asn13 of the P2Y12 receptor are not required for its surface expression. A: Plasmid DNA of pWZ1002
(wild-type receptor), pWZ1006 (N6Q mutant), pWZ1007 (N13Q mutant), and pWZ1008 (N6Q/N13Q mutant), were transiently transfected into
COS-7 cells as described in Section 2. 50 Wg/ml of crude membranes isolated from these cells were subjected to 4^20% SDS^PAGE and immu-
noblotted with rat monoclonal anti-HA 3F10 antibody. B: Flow cytometry analysis indicates that the P2Y12 receptors missing either or both
N-linked glycosylation sites have a normal cell surface expression. COS-7 cells, transiently transfected with wild-type or mutant P2Y12-express-
ing plasmids, were stained with anti-HA 3F10 antibody or isotypic rat IgG1, and subjected to FACS analysis, as described in Section 2.
FEBS 28174 15-3-04
X. Zhong et al./FEBS Letters 562 (2004) 111^117114
(N6Q, N13Q, N6Q/N13Q), the COS-7 cells transiently ex-
pressing the mutant and wild-type receptors were measured
for the saturation whole cell binding of [3H]2MeSADP (Fig.
4A). The results showed that Bmax of mutants N6Q (1.82
pmol/106 cells), N13Q (1.50 pmol/106 cells), N6Q/N13Q
(0.97 pmol/106 cells), and wild-type (1.47 pmol/106 cells) are
similar, whereas the Kd of the three mutants (11.3, 9.6, 14 nM,
respectively) slightly increased as compared to wild-type (5.6
nM). To ¢nd out whether the binding speci¢city of the non-
glycosylated mutant receptor is a¡ected, competition experi-
ments were carried out for the COS-7 cells transiently express-
ing wild-type and N6Q/N13Q mutant receptors. As shown in
Fig. 4B, both wild-type and N6Q/N13Q mutant receptors dis-
play similar competition curves for 2MeSADP and 2Me-
SAMP. The N6Q/N13Q mutant has a slightly decreased
IC50 of 2MeSADP (6.3 nM) in comparison with wild-type
(20 nM), while the IC50 of 2MeSAMP for wild-type (4 WM)
and N6Q/N13Q (2.5 WM) were similar. Taken together, these
data indicate that the elimination of either or both N-linked
glycosylation sites does not appear to have a signi¢cant e¡ect
on a⁄nity or speci¢city of ligand binding to P2Y12 receptor.
3.4. N-linked glycosylation is important for the P2Y12-mediated
inhibition of adenylyl cyclase
It has been previously shown that P2Y12 receptor is coupled
to a Gi-mediated signaling pathway, which inhibits adenylyl
cyclase [9,10]. To assess whether N-linked glycosylation plays
a role in the signal transduction function of the receptor after
ligand binding, stably expressed CHO cells of wild-type and
N6Q/N13Q mutant HA-P2Y12 receptors were constructed. As
shown in the inset in Fig. 5, the cell lines of wild-type and
N6Q/N13Q mutant receptors possess similar [3H]2MeSADP
binding levels and binding patterns, indicating that the expres-
sion levels of the receptors are similar. The e¡ect of P2Y12
activation on the adenylyl cyclase activity in these cells was
then measured. As described in Section 2, the P2Y12-express-
ing CHO cells were challenged with 1 WM forskolin and the
cellular cAMP contents were strongly increased. When the
cells were co-stimulated with di¡erent concentrations of 2Me-
SADP, the intracellular levels of cAMP in the wild-type HA-
P2Y12-expressing cells decreased in a concentration-dependent
manner (Fig. 5). No such inhibition was observed when per-
formed on non-transfected CHO cells (data not shown). The
EC50 value of 2MeSADP for the wild-type HA-P2Y12-express-
ing cells is around 0.4 nM, which is within the previously
reported values ranging from 0.078 to 14 nM [9,22^23]. How-
ever, when the N6Q/N13Q mutant HA-P2Y12-expressing cells
were co-stimulated with 2MeSADP and forskolin, no inhibi-
tory response to the forskolin-induced cAMP accumulation
was observed (Fig. 5). 2MeSADP failed to trigger a concen-
tration-dependent inhibition of the adenylyl cyclase activity in
the cells expressing the non-glycosylated mutant receptor,
even though the mutant receptor had a similar [3H]2MeSADP
binding activity to the wild-type receptor. Thus, these results
indicate that although the non-glycosylated P2Y12 receptor is
functional in the ligand binding, it is defective in signal trans-
duction.
4. Discussion
This study demonstrates that two potential N-linked glyco-
sylation sites of the P2Y12 receptor are both glycosylated in
vivo, and that N-linked glycosylation is essential for signal
transduction but not for the receptor’s expression on the
cell surface and ligand binding activity. This conclusion is
Fig. 4. N-linked glycosylation is not required for the ligand binding
activity of the P2Y12 receptor. A: Saturation binding of
[3H]2MeSADP to the COS-7 cells transiently transfected with
P2Y12-expressing plasmids. The [3H]2MeSADP binding assays, as
described in Section 2, were performed in COS-7 cells transfected
with wild-type or mutant P2Y12 receptor cDNAs. B: Competition
for [3H]2MeSADP binding to the COS-7 cells expressing wild-type
and non-glycosylated mutant P2Y12 receptors. COS-7 cells, transi-
ently transfected with plasmid DNAs expressing wild-type and
N6Q/N13Q mutant receptors, were incubated with 10 nM
[3H]2MeSADP and di¡erent concentrations of 2MeSADP or 2Me-
SAMP. All data represent the meansUS.D. (n=4).
Fig. 5. N-linked glycosylation is important for the P2Y12-mediated
inhibition of adenylyl cyclase. The concentration-dependent inhibi-
tion by 2MeSADP of the forskolin-induced cAMP accumulation
in the HA-P2Y12 stably expressed CHO cells were performed as
described in Section 2. Both wild-type and N6Q/N13Q mutant re-
ceptor-expressing CHO cells were treated with IBMX (1 mM) and
challenged with forskolin (1 WM) and 2MeSADP. The cAMP con-
centrations in the presence of IBMX alone, and in the presence of
forskolin and IBMX, were normalized to 0 and 100%, respectively.
The data represent the meansUS.D. (n=4). The graph in the inset
compares the [3H]2MeSADP binding on crude membrane fractions
isolated from the same cells. The data represent the meansUS.D.
(n=2).
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supported by the evidence obtained from two di¡erent ap-
proaches. First, in stably expressing P2Y12 CHO cells, tunica-
mycin, an inhibitor of N-linked glycosylation, causes no e¡ect
on the surface expression and ligand binding of the receptor.
The inhibition of N-linked glycosylation by tunicamycin is
con¢rmed by a shift in the molecular weight of the protein
in the tunicamycin-treated cells. Second, because tunicamycin
has a general action on glycoprotein synthesis, the consensus
N-linked glycosylation sequences have been removed by site-
directed mutagenesis. The mutated non-glycosylated receptor
retains cell surface expression and ligand binding activity.
Furthermore, the study also revealed that the N-linked carbo-
hydrate addition is instead required for the signal transducing
step of the receptor, as the unglycosylated mutant receptor is
defective in the P2Y12-mediated inhibition of the adenylyl cy-
clase activity despite a normal binding activity. This study is
the ¢rst report to describe the roles of N-linked glycosylation
in the normal activity of purinergic receptors of the P2Y sub-
class.
The data from this study suggest that the folding and the
delivery of P2Y12 receptor to the cell surface are apparently
independent of the oligosaccharide addition process. This is
clearly in contrast to those of the P2X receptors where N-
linked glycans have been shown to play an essential role for
their surface expression [17^20]. It has been speculated that
N-glycan modi¢cation a¡ects the oligomer assembly or initial
folding of the receptors for further intracellular tra⁄cking
[17,19,20]. P2X receptors have two transmembrane domains
and a large extracellular loop, while P2Y receptors contain
seven transmembrane domains. The di¡erence in topological
arrangement between P2X receptors and P2Y receptors may
re£ect the di¡erence in membrane tra⁄cking requirement be-
tween these two types of purinergic receptors. It will be inter-
esting to ¢nd out the roles of N-linked glycans on the surface
expression of other P2Y receptors.
One surprising ¢nding of this study is that the N-glycans at
the extracellular amino-terminus of the P2Y12 receptor are
involved in the signal transducing step after the ligand is
bound. It may imply that a conformational change of the
extracellular amino-terminus a¡ected may be required for sig-
nal transfer through the membrane upon agonist ligation.
This result is consistent with a recent report [24] that the third
extracellular loop (EL3) of the P2Y12 receptor appears to be
crucial for postoccupancy signaling. Two autosomal P2Y12
mutations (one within EL3 and the other at the boundaries
of EL3 and TM6), identi¢ed from a patient with a congenital
bleeding disorder, result in a normal 2MeSADP binding but a
defective ADP-dependent inhibition of forskolin-stimulated
adenylyl cyclase activity [24]. It seems that the extracellular
portions of the P2Y12 receptor including its amino-terminus
and extracellular loops are directly involved in the signal
transfer to the cytoplasm, through a conformational change
triggered by the ligand binding at the transmembrane domain
regions.
N-linked glycan structures of P2Y12 expressed on platelets
are still unknown. Even though P2Y12 expressed on CHO cells
that generally produce bi-, tri- and tetra-antennary sialylated
glycans, is functional, yet the e¡ect of di¡erent glycan struc-
tures on its surface expression, ligand binding or signalling
remains unknown. It will be interesting to examine P2Y12 ex-
pressed on various CHO glycosylation mutants [25] producing
hybrid, high mannose and truncated complex carbohydrates
or produced in presence of various N-linked glycosylation
inhibitors. It will also be interesting to ¢nd out whether re-
furbishing either of N-linked glycans to P2Y12 will restore the
signal transduction function. Further detailed experiments will
be needed to address all these questions.
In summary, the present study demonstrates that although
N-linked glycosylation is not absolutely required for cell sur-
face expression and ligand binding of the P2Y12 receptor, it is
important for the signal transducing step upon ligand binding.
As P2X1, P2X2, and P2X4 have similar functional consequen-
ces of blocking N-linked glycosylation, it is possible that other
members of the P2Y family might share the phenotype of the
P2Y12 receptor.
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